The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO GI 2021 | Phase II trial of neoadjuvant bevacizumab + modified FOLFOX7 in rectal cancer

Name: Phase II trial of neoadjuvant bevacizumab + modified FOLFOX7 in rectal cancer
Uploaded: 2021-01-18T00:00:00Z
Duration: 4 min 3 s
Description: Afsaneh Barzi, MD, PhD, City of Hope Comprehensive Cancer Center, Duarte, CA, discusses the results of a Phase II trial of neoadjuvant bevacizumab with modified FOLFOX7 in lieu of radiation in patients with stage II and III rectal cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Afsaneh Barzi • 18 Jan 2021

ASCO GI 2021

Gastrointestinal Cancer Rectal Cancer Bevacizumab FOLFOX

Afsaneh Barzi, MD, PhD, City of Hope Comprehensive Cancer Center, Duarte, CA, discusses the results of a Phase II trial of neoadjuvant bevacizumab with modified FOLFOX7 in lieu of radiation in patients with stage II and III rectal cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).